Addex Therapeutics (FRA:APE1) Common Stock: €2.40 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:APE1 Addex Therapeutics Ltd FRA:APE1
7 GF Score
Price €4.92
GF Value €1.25
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics Common Stock?

Addex Therapeutics FRA:APE1 -6.29% 7 Common Stock is €2.40 Mil as of Mar. 2026. GuruFocus rates FRA:APE1 with a GF Score™ of 7/100 and a GF Value™ of €1.25. The stock has 6 warning signs investors should review.

Addex Therapeutics's quarterly common stock increased from Sep. 2025 (€1.97 Mil) to Dec. 2025 (€2.34 Mil) and increased from Dec. 2025 (€2.34 Mil) to Mar. 2026 (€2.40 Mil).

Addex Therapeutics's annual common stock increased from Dec. 2023 (€1.96 Mil) to Dec. 2024 (€1.98 Mil) and increased from Dec. 2024 (€1.98 Mil) to Dec. 2025 (€2.34 Mil).

Addex Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Common Stock Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.35 1.17 1.96 1.98 2.34

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.93 1.97 1.97 2.34 2.40
FRA:APE1
7GF Score
Addex Therapeutics Ltd FRA:APE1
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Addex Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €2.40 Mil mean?
Addex Therapeutics (FRA:APE1) has a Common Stock of €2.40 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Addex Therapeutics and its competitors.
Is Addex Therapeutics' Common Stock too high?
Addex Therapeutics' current Common Stock is €2.40 Mil. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' Common Stock compare to VRTX and REGN?
Addex Therapeutics' Common Stock of €2.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current Common Stock is €2.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current Common Stock of €2.40 Mil. The stock's GF Value™ is €1.25, compared to a current price of €4.92 — trading 293.6% above its estimated fair value. The current Common Stock is €2.40 Mil. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current Common Stock is €2.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?

Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued. The current stock price of €4.92 is trading 293.6% above its estimated GF Value™ of €1.25.

Key valuation signals for FRA:APE1:

  • Common Stock: €2.40 Mil
  • GF Value™: €1.25 vs. price of €4.92 (293.6% above fair value)
  • GF Score™: 7/100 with 6 warning signs

No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score

Get the complete analysis for FRA:APE1

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.92
Price
€1.25
GF Value